{"id":295,"date":"2019-11-11T20:44:40","date_gmt":"2019-11-11T19:44:40","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=295"},"modified":"2021-07-20T08:25:42","modified_gmt":"2021-07-20T06:25:42","slug":"mt-7117-endeavor-study-for-epp","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/","title":{"rendered":"MT-7117 ENDEAVOR Study for EPP"},"content":{"rendered":"\n<p>Today, in a press release Mitsubishi Tanabe Pharma Corporation announced results of the MT-7117 ENDEAVOR study for EPP. MT-7117 (<a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Dersimelagon\"><strong>dersimelagon<\/strong><\/a>) is a synthetic, orally-administered, non-peptide small molecule, acting as agonist of the melanocortin-1 receptor (MC1R), the same receptor targeted by afamelanotide.<\/p>\n\n\n\n<p>This is good news for the EPP patient community, whose needs have long been neglected by drug developers until afamelanotide rose on the EPP horizon in 2006. Having another industry player working to address patient needs could potentially lead to a therapeutic alternative and stimulate further knowledge around EPP and treatment attributes important to patients.<\/p>\n\n\n\n<p>According to the press release, the results of the ENDEAVOR study will be presented at a scientific congress in early 2020. The IPPN looks very much forward to understanding more about the safety and efficacy of MT-7117 from these results as well as about the study design and the endpoints used to assess the potential of this drug candidate.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.mt-pharma.co.jp\/e\/release\/nr\/2019\/pdf\/e_MTPC191111.pdf\"><strong>Press Release on the ENDEAVOR study<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Today, in a press release Mitsubishi Tanabe Pharma Corporation announced results of the MT-7117 ENDEAVOR study for EPP. MT-7117 (dersimelagon) is a synthetic, orally-administered, non-peptide small molecule, acting as agonist of the melanocortin-1 receptor (MC1R), the same receptor targeted by afamelanotide. This is good news for the EPP patient community, whose needs have long been&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MT-7117 ENDEAVOR Study for EPP - International Porphyria Patient Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MT-7117 ENDEAVOR Study for EPP - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"Today, in a press release Mitsubishi Tanabe Pharma Corporation announced results of the MT-7117 ENDEAVOR study for EPP. MT-7117 (dersimelagon) is a synthetic, orally-administered, non-peptide small molecule, acting as agonist of the melanocortin-1 receptor (MC1R), the same receptor targeted by afamelanotide. This is good news for the EPP patient community, whose needs have long been&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-11T19:44:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-20T06:25:42+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"MT-7117 ENDEAVOR Study for EPP\",\"datePublished\":\"2019-11-11T19:44:40+00:00\",\"dateModified\":\"2021-07-20T06:25:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\"},\"wordCount\":165,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\",\"name\":\"MT-7117 ENDEAVOR Study for EPP - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2019-11-11T19:44:40+00:00\",\"dateModified\":\"2021-07-20T06:25:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MT-7117 ENDEAVOR Study for EPP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MT-7117 ENDEAVOR Study for EPP - International Porphyria Patient Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/","og_locale":"en_US","og_type":"article","og_title":"MT-7117 ENDEAVOR Study for EPP - International Porphyria Patient Network","og_description":"Today, in a press release Mitsubishi Tanabe Pharma Corporation announced results of the MT-7117 ENDEAVOR study for EPP. MT-7117 (dersimelagon) is a synthetic, orally-administered, non-peptide small molecule, acting as agonist of the melanocortin-1 receptor (MC1R), the same receptor targeted by afamelanotide. This is good news for the EPP patient community, whose needs have long been&hellip;","og_url":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2019-11-11T19:44:40+00:00","article_modified_time":"2021-07-20T06:25:42+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"MT-7117 ENDEAVOR Study for EPP","datePublished":"2019-11-11T19:44:40+00:00","dateModified":"2021-07-20T06:25:42+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/"},"wordCount":165,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/","url":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/","name":"MT-7117 ENDEAVOR Study for EPP - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2019-11-11T19:44:40+00:00","dateModified":"2021-07-20T06:25:42+00:00","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2019\/11\/mt-7117-endeavor-study-for-epp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"MT-7117 ENDEAVOR Study for EPP"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/295"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=295"}],"version-history":[{"count":8,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/295\/revisions"}],"predecessor-version":[{"id":303,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/295\/revisions\/303"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}